Company Filing History:
Years Active: 2019-2024
Title: Renaud Buffet: Innovator in Cancer Treatment
Introduction
Renaud Buffet is a notable inventor based in Boulogne, France. He has made significant contributions to the field of cancer treatment, particularly in the area of peripheral T cell lymphoma. With a total of 5 patents to his name, Buffet's work is paving the way for innovative therapeutic approaches.
Latest Patents
Renaud Buffet's latest patents focus on compounds that specifically bind to KIR3DL2 and NKp46 for the treatment of peripheral T cell lymphoma. One of his inventions relates to methods for the treatment, prevention, and diagnosis of this type of lymphoma using compounds that bind KIR3DL2. This invention also includes the use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays. Another significant patent involves methods for treating peripheral T cell lymphoma using compounds that bind NKp46, which deplete tumor cells expressing NKp46 on their surface. This patent also discusses the use of antibodies that bind NKp46 in diagnostic and theranostic applications.
Career Highlights
Renaud Buffet is currently associated with Innate Pharma, a company dedicated to developing innovative immunotherapies for cancer treatment. His work at Innate Pharma has been instrumental in advancing research and development in the field of oncology.
Collaborations
Renaud Buffet collaborates with esteemed colleagues such as Cécile Bonnafous and Hélène Sicard. Their combined expertise contributes to the innovative research being conducted at Innate Pharma.
Conclusion
Renaud Buffet's contributions to cancer treatment through his patents and work at Innate Pharma highlight his role as a leading inventor in the field. His innovative approaches are crucial for the future of therapeutic options for patients with peripheral T cell lymphoma.